US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

593.41

-26.4041-4.26%

Number of Gainers:18

Number of Losers:140

Number of Flat:9

PE:- -

High:619.76

Open:619.76

Low:592.62

Close:619.81

Volume:312.05M

Turnover:8.72B

Market Cap:445.81B

Float Cap:320.26B

Loading ...

PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress

Morning Insights by Zhang Xiaojie

VTEX files initial beneficial ownership statement; CFO Ricardo Sodre reports 471,124 Class A common shares

Trump to sign executive order paying TSA amid DHS shutdown, Bloomberg says

Corrected-Century Therapeutics Inc - Sold $18.4 Mln in Common Stock Through TD Cowen - SEC Filing (Not 'May Offer $150 Mln')

THOMSON REUTERS

Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary

Inspira Technologies Oxy FY EPS $(0.45) Misses $(0.44) Estimate, Sales $289.000K Miss $19.493M Estimate

Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million

Paymentus General Counsel Andrew Gerber Announces Upcoming Departure

Century Therapeutics Updates ATM Program to Enhance Liquidity

Inspira Technologies Ends Bio-View Deal, Strengthens Nasdaq Compliance as 2025 Loss Narrows Growth Path

EpicQuest Education Group International filed Form 3; Director Gary Michael Pratt reports 1,775 ordinary shares beneficially owned

Century Therapeutics updates $150.0 million ATM program; $131.6 million remains available for sale

Century Therapeutics Inc - May Offer up to $150 Mln in Common Stock Through TD Cowen - SEC Filing

THOMSON REUTERS

Acumen files to sell 10.83M shares of common stock for holders

Paymentus General Counsel Andrew Gerber departs; last day April 6, 2026

Nuvalent; CFO Alexandra Balcom drops 25,130 common shares valued at $2,465,000

Sprinklr; CTO Amitabh Misra disposes of 41,667 common shares; $243,000

Acumen Pharmaceuticals Inc - Files for Offering of up to 10,833,331 Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

Press Release: Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4539/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":593.40814,"timestamp":1774641599999,"preClose":619.8122,"halted":0,"volume":312051776,"delay":0,"changeRate":-0.0426,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-26.404053,"latestTime":"03-27 16:00:00 EDT","open":619.76276,"high":619.76447,"low":592.62305,"amount":8716790920.053452,"amplitude":0.04379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.090165,"peRate":168.263558,"turnoverRate":0.022172,"increases":18,"decrements":140,"flats":4,"marketCap":445810669823.375,"floatMarketCap":320261614730.4375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":619.76447,"amplitude":0.04379,"preClose":619.8122,"low":592.62305,"pbRate":"5.090165","latestPrice":593.40814,"volume":312051776,"delay":0,"open":619.76276,"prevYearClose":881.5255,"prevWeekClose":652.8748,"prevMonthClose":663.4647,"prevQuarterClose":881.5255,"fiveDayClose":652.8748,"twentyDayClose":663.4647,"sixtyDayClose":897.8409,"secType":"PLATE","market":"US","turnoverRate":0.022172,"peRate":168.263558,"marketCap":445810669823.375,"floatMarketCap":320261614730.4375,"timestamp":1774641599999,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":18,"down":140,"flat":9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622889754","title":"PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622889754?lang=en_us&edition=fundamental","pubTime":"2026-03-27 07:19","pubTimestamp":1774567153,"startTime":"0","endTime":"0","summary":"The latest announcement is out from PYC Therapeutics Limited ( ($AU:PYC) ). PYC Therapeutics is advancing its PYC-003 drug candidate, designed to a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-to-showcase-pkd-drug-progress-at-world-nephrology-congress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-to-showcase-pkd-drug-progress-at-world-nephrology-congress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4097","BK4007","LU2065732104.USD","BK4139","BK4539","PKD","PRGS"],"gpt_icon":0},{"id":"1198563818","title":"Morning Insights by Zhang Xiaojie","url":"https://stock-news.laohu8.com/highlight/detail?id=1198563818","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198563818?lang=en_us&edition=fundamental","pubTime":"2026-03-27 07:11","pubTimestamp":1774566670,"startTime":"0","endTime":"0","summary":"Zhang Xiaojie presents Morning Insights, delivering a wealth of information and precise analysis exclusively available through the SINA Corp financial application.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0056508442.USD","IE00B894F039.SGD","IE00BZ9MQY76.HKD","BK4585","LU0353189680.USD","LU2360106780.USD","LU1852331112.SGD","LU2250418816.HKD","LU1861220033.SGD","LU0097036916.USD","APPX","LU2087625088.SGD","SINA","BK4023","BK4588","LU0353189763.USD","LU2290526834.HKD","BK4539","BK4608","BK4613","IE00B19Z9Z06.USD","LU2360107168.USD","LU1861215975.USD","LU2063271972.USD","APP","IE00B19Z9P08.USD"],"gpt_icon":0},{"id":"2622289299","title":"VTEX files initial beneficial ownership statement; CFO Ricardo Sodre reports 471,124 Class A common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289299","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622289299?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:45","pubTimestamp":1774565150,"startTime":"0","endTime":"0","summary":"VTEX Chief Financial Officer Ricardo Sodre filed an initial statement of beneficial ownership reporting 471,124 Class A common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VTEX published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6qbNnV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4116","BK4549","VTEX","BK4077"],"gpt_icon":0},{"id":"2622892630","title":"Trump to sign executive order paying TSA amid DHS shutdown, Bloomberg says","url":"https://stock-news.laohu8.com/highlight/detail?id=2622892630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622892630?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:40","pubTimestamp":1774564843,"startTime":"0","endTime":"0","summary":"Publicly traded companies in the airline space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), Frontier Group (ULCC), Jet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trump-to-sign-executive-order-paying-tsa-amid-dhs-shutdown-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trump-to-sign-executive-order-paying-tsa-amid-dhs-shutdown-bloomberg-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DAL","IE00BFMHRM44.USD","BK4585","ULCC","BK4008","BK4588","ARKX","LU0128525689.USD","BK4544","DHS","BK4547","LU1267930227.SGD","AAL","LU0310800965.SGD","AALG","LU0052756011.USD","UFO","BK4564","ALK","BK4500","BK4539"],"gpt_icon":0},{"id":"2622894115","title":"Corrected-Century Therapeutics Inc - Sold $18.4 Mln in Common Stock Through TD Cowen - SEC Filing (Not 'May Offer $150 Mln')","url":"https://stock-news.laohu8.com/highlight/detail?id=2622894115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622894115?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:00","pubTimestamp":1774562450,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E2LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IPSC","BK4539","BK4505"],"gpt_icon":0},{"id":"2622894336","title":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622894336","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622894336?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:38","pubTimestamp":1774561121,"startTime":"0","endTime":"0","summary":"Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings SummaryRani Therapeutics Holdings Inc RANI.OQ reported a quarterly adjusted loss of 12 cents per share for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E2KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RANI","BK4007"],"gpt_icon":0},{"id":"2622289486","title":"Inspira Technologies Oxy FY EPS $(0.45) Misses $(0.44) Estimate, Sales $289.000K Miss $19.493M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289486","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622289486?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:32","pubTimestamp":1774560762,"startTime":"0","endTime":"0","summary":"Inspira Technologies Oxy (NASDAQ:IINN) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 25 percent increase over losses of $(0.60) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51498114/inspira-technologies-oxy-fy-eps-0-45-misses-0-44-estimate-sales-289-000k-miss-19-493m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Inspira Technologies Oxy FY EPS $(0.45) Misses $(0.44) Estimate, Sales $289.000K Miss $19.493M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IINN","BK4082","BK4539"],"gpt_icon":0},{"id":"2622891491","title":"Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891491?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:17","pubTimestamp":1774559838,"startTime":"0","endTime":"0","summary":"Dermata filed a Form 8-K reporting full-year 2025 results, including a net loss of USD 7.6 million.Research and development expense fell 64.27% to USD 2.9 million, primarily due to lower clinical costs after completion of the STAR-1 acne study in Q2 2025.Selling, general and administrative expense rose 12.42% to USD 4.8 million, driven mainly by USD 0.7 million in marketing expense.Cash and cash equivalents were USD 7.5 million as of Dec. 31, 2025, and the company said its cash resources are expected to fund operations into Q1 2027.Management said Dermata is pivoting to direct-to-consumer skincare under the Tome brand, with a first product launch targeted for mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2J3K1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","DRMA"],"gpt_icon":0},{"id":"2622917318","title":"Paymentus General Counsel Andrew Gerber Announces Upcoming Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=2622917318","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622917318?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:07","pubTimestamp":1774559262,"startTime":"0","endTime":"0","summary":"Paymentus Holdings ( ($PAY) ) has issued an update. Paymentus Holdings, Inc. announced that its General Counsel and Corporate Secretary, Andrew Ger...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/paymentus-general-counsel-andrew-gerber-announces-upcoming-departure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/paymentus-general-counsel-andrew-gerber-announces-upcoming-departure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4106","PAY","BK4227"],"gpt_icon":0},{"id":"2622787891","title":"Century Therapeutics Updates ATM Program to Enhance Liquidity","url":"https://stock-news.laohu8.com/highlight/detail?id=2622787891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622787891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:04","pubTimestamp":1774559075,"startTime":"0","endTime":"0","summary":"Century Therapeutics ( ($IPSC) ) has shared an announcement. On July 10, 2025, Century Therapeutics, Inc. filed a new shelf registration statement ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/century-therapeutics-updates-atm-program-to-enhance-liquidity?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/century-therapeutics-updates-atm-program-to-enhance-liquidity?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPSC","BK4505","BK4139","BK4539"],"gpt_icon":0},{"id":"2622089122","title":"Inspira Technologies Ends Bio-View Deal, Strengthens Nasdaq Compliance as 2025 Loss Narrows Growth Path","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089122?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:03","pubTimestamp":1774559032,"startTime":"0","endTime":"0","summary":"Inspira Technologies Oxy BHN ( ($IINN) ) has issued an update. Inspira Technologies reported full-year 2025 results on March 26, 2026, highlighting...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inspira-technologies-ends-bio-view-deal-strengthens-nasdaq-compliance-as-2025-loss-narrows-growth-path?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inspira-technologies-ends-bio-view-deal-strengthens-nasdaq-compliance-as-2025-loss-narrows-growth-path?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","BK4539","BK4082","IINN"],"gpt_icon":0},{"id":"2622891581","title":"EpicQuest Education Group International filed Form 3; Director Gary Michael Pratt reports 1,775 ordinary shares beneficially owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891581","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891581?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:01","pubTimestamp":1774558913,"startTime":"0","endTime":"0","summary":"EpicQuest Education Group International filed Form 3; Director Gary Michael Pratt reports 1,775 ordinary shares beneficially owned. EpicQuest said director Gary Michael Pratt filed an initial Form 3 reporting 1,775 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EpicQuest Education Group International Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLS2TP2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EEIQ","BK4539","BK4204"],"gpt_icon":0},{"id":"2622899213","title":"Century Therapeutics updates $150.0 million ATM program; $131.6 million remains available for sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899213","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899213?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:43","pubTimestamp":1774557793,"startTime":"0","endTime":"0","summary":"Century Therapeutics filed a new prospectus supplement for its at-the-market equity offering program for up to USD 150.0 million in common stock sales.TD Securities  is acting as sales agent under a sales agreement dated July 1, 2022.Common stock sold under the program totaled USD 18.38 million, leaving USD 131.62 million available for future sales.The company said its new shelf registration statement on Form S-3 became effective on January 9, 2026, replacing its prior shelf registration statement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL1W0SSN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IPSC","BK4139","BK4539"],"gpt_icon":0},{"id":"2622989923","title":"Century Therapeutics Inc - May Offer up to $150 Mln in Common Stock Through TD Cowen - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989923?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:42","pubTimestamp":1774557765,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E155:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4505","IPSC","BK4139"],"gpt_icon":0},{"id":"2622899401","title":"Acumen files to sell 10.83M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899401","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899401?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:35","pubTimestamp":1774557357,"startTime":"0","endTime":"0","summary":"16:31 EDT Acumen (ABOS) files to sell 10.83M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mark...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acumen-files-to-sell-10-83m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acumen-files-to-sell-10-83m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ABOS","BK4539"],"gpt_icon":0},{"id":"2622990899","title":"Paymentus General Counsel Andrew Gerber departs; last day April 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622990899","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622990899?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:35","pubTimestamp":1774557346,"startTime":"0","endTime":"0","summary":"Paymentus General Counsel and Corporate Secretary Andrew Gerber said he will leave the company to pursue a role outside the industry.His departure was described as not related to any disagreement with Paymentus.Gerber’s last day is set for April 6, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paymentus Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbft1hv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4106","PAY","BK4539","BK4227"],"gpt_icon":0},{"id":"2622995718","title":"Nuvalent; CFO Alexandra Balcom drops 25,130 common shares valued at $2,465,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622995718","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622995718?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:31","pubTimestamp":1774557107,"startTime":"0","endTime":"0","summary":"Nuvalent Chief Financial Officer Alexandra Balcom exercised stock options for 11,430 shares at USD 1.08 per share.She sold 2,599 shares at USD 95.03 per share.Additional sales included 7,671 shares at USD 95.88 per share and 1,160 shares at USD 96.5 per share.A separate transaction reported the sale of 13,700 shares at USD 100.16 per share.Following the reported transactions, Balcom beneficially owned 85,533 shares of Class A common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3ZgPpL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuvalent; CFO Alexandra Balcom drops 25,130 common shares valued at $2,465,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"2622789957","title":"Sprinklr; CTO Amitabh Misra disposes of 41,667 common shares; $243,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789957","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789957?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:31","pubTimestamp":1774557077,"startTime":"0","endTime":"0","summary":"Sprinklr Chief Technology Officer Amitabh Misra reported a sale of 41,667 Class A common shares.The transaction was priced at USD 5.82 per share.Misra reported direct ownership of 929,086 Class A common shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprinklr Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7281r6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sprinklr; CTO Amitabh Misra disposes of 41,667 common shares; $243,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","CXM","BK4539"],"gpt_icon":0},{"id":"2622995428","title":"Acumen Pharmaceuticals Inc - Files for Offering of up to 10,833,331 Common Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622995428","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622995428?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:30","pubTimestamp":1774557046,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABOS","BK4139","BK4539"],"gpt_icon":0},{"id":"2622899638","title":"Press Release: Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899638","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899638?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:30","pubTimestamp":1774557000,"startTime":"0","endTime":"0","summary":"RA'ANANA, Israel, March 26, 2026  -- Inspira Technologies OXY B.H.N. Ltd.  , a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update.Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: \"2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA ART100 system, including active clinical use at leading medical centers, advancement of a submitted quotation into a capital intake process at a leading U.S. academic medical center, and continued expansion of our commercial footprint. In parallel, we are engaged in ongoing discussions with multiple medical device companies regarding broader strategic collaboration frameworks and other potential value-creating opportunities to support the Comp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IINN","BK4099","BK4539","03160","BK4082","TM","BK4588","BK4555","BK4585","BK4604"],"gpt_icon":0}],"pageSize":20,"totalPage":75,"pageCount":7,"totalSize":1493,"code":"91000000","status":"200"}]}}